Shenyang Xingqi Pharma Gains NMPA Approval to Initiate Clinical Trials for SQ-25012 Injection in Thyroid Eye Disease

Stock News

Yesterday

Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration (NMPA) for its SQ-25012 injection, granting permission to conduct clinical trials for the treatment of thyroid eye disease.

SQ-25012 injection is a recombinant humanized IgG1-type trispecific antibody, classified as a Class 1 innovative therapeutic biologic developed by the company, intended for the clinical treatment of thyroid eye disease.

In accordance with the requirements for Class 1 innovative injectable therapeutic biologics, the company has completed comprehensive research on SQ-25012 injection, including pharmaceutical, non-clinical pharmacology, and toxicology studies. The findings demonstrate that SQ-25012 injection possesses favorable safety profiles and significant clinical development value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1106452599"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106452599\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106452599?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106452599","market":"us","top_or_hot":-1,"title":"Shenyang Xingqi Pharma Gains NMPA Approval to Initiate Clinical Trials for SQ-25012 Injection in Thyroid Eye Disease","media":"Stock News","content":"<p><b>Shenyang Xingqi Pharmaceutical Co., Ltd.</b> (<b>300573.SZ</b>) has announced that it recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA) for its SQ-25012 injection, granting permission to conduct clinical trials for the treatment of thyroid eye disease.<br><br>SQ-25012 injection is a recombinant humanized IgG1-type trispecific antibody, classified as a Class 1 innovative therapeutic biologic developed by the company, intended for the clinical treatment of thyroid eye disease.<br><br>In accordance with the requirements for Class 1 innovative injectable therapeutic biologics, the company has completed comprehensive research on SQ-25012 injection, including pharmaceutical, non-clinical pharmacology, and toxicology studies. The findings demonstrate that SQ-25012 injection possesses favorable safety profiles and significant clinical development value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenyang Xingqi Pharma Gains NMPA Approval to Initiate Clinical Trials for SQ-25012 Injection in Thyroid Eye Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenyang Xingqi Pharma Gains NMPA Approval to Initiate Clinical Trials for SQ-25012 Injection in Thyroid Eye Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-15 15:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Shenyang Xingqi Pharmaceutical Co., Ltd.</b> (<b>300573.SZ</b>) has announced that it recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA) for its SQ-25012 injection, granting permission to conduct clinical trials for the treatment of thyroid eye disease.<br><br>SQ-25012 injection is a recombinant humanized IgG1-type trispecific antibody, classified as a Class 1 innovative therapeutic biologic developed by the company, intended for the clinical treatment of thyroid eye disease.<br><br>In accordance with the requirements for Class 1 innovative injectable therapeutic biologics, the company has completed comprehensive research on SQ-25012 injection, including pharmaceutical, non-clinical pharmacology, and toxicology studies. The findings demonstrate that SQ-25012 injection possesses favorable safety profiles and significant clinical development value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMED","symbol_name":"iShares Health Innovation Active ETF","start_time":0,"source_url":"","article_id":"1106452599","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106452599","pubTimestamp":1789459095,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA)...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300573":"兴齐眼药","BMED":"iShares Health Innovation Active ETF","PSYK":"PSYK ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","MDTX":"Corgi MediaTek 2x Daily ETF","BK0239":"医药制造","IBBQ":"Invesco Nasdaq Biotechnology ETF","BK0177":"最小市值"},"translate_title":"沈阳星旗药业获NMPA批准启动SQ-25012注射液治疗甲状腺眼病的临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300573":1,"BMED":1,"MDTX":1,"IBBQ":1,"PSYK":1,"IBBJ":1},"content_text":"Shenyang Xingqi Pharmaceutical Co., Ltd. (300573.SZ) has announced that it recently received the \"Drug Clinical Trial Approval Notice\" issued by the National Medical Products Administration (NMPA) for its SQ-25012 injection, granting permission to conduct clinical trials for the treatment of thyroid eye disease.SQ-25012 injection is a recombinant humanized IgG1-type trispecific antibody, classified as a Class 1 innovative therapeutic biologic developed by the company, intended for the clinical treatment of thyroid eye disease.In accordance with the requirements for Class 1 innovative injectable therapeutic biologics, the company has completed comprehensive research on SQ-25012 injection, including pharmaceutical, non-clinical pharmacology, and toxicology studies. The findings demonstrate that SQ-25012 injection possesses favorable safety profiles and significant clinical development value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}